Pieris Pharmaceuticals Inc (PIRS) Receives Average Recommendation of “Buy” from Brokerages

Share on StockTwits

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been assigned an average rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.33.

A number of research firms have issued reports on PIRS. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Pieris Pharmaceuticals in a research report on Friday, March 9th. Jefferies Financial Group began coverage on Pieris Pharmaceuticals in a research report on Monday, March 19th. They issued a “buy” rating and a $12.00 target price on the stock. BidaskClub cut Pieris Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 15th. Cowen began coverage on Pieris Pharmaceuticals in a research report on Friday, May 4th. They issued an “outperform” rating on the stock. Finally, ValuEngine upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.

In other news, insider Orbimed Advisors Llc sold 1,000,000 shares of Pieris Pharmaceuticals stock in a transaction dated Monday, April 30th. The stock was sold at an average price of $6.35, for a total transaction of $6,350,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James A. Geraghty purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, May 15th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $57,500.00. Following the completion of the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $115,000. The disclosure for this purchase can be found here. Insiders own 5.07% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its stake in shares of Pieris Pharmaceuticals by 24.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 71,400 shares of the biotechnology company’s stock valued at $487,000 after purchasing an additional 13,800 shares in the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter valued at about $103,000. Cetera Advisor Networks LLC acquired a new stake in shares of Pieris Pharmaceuticals during the fourth quarter valued at about $124,000. Bank of Montreal Can acquired a new stake in shares of Pieris Pharmaceuticals during the fourth quarter valued at about $144,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter valued at about $136,000. 63.09% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ PIRS traded down $0.02 during mid-day trading on Tuesday, reaching $5.19. The company had a trading volume of 2,057,814 shares, compared to its average volume of 572,769. Pieris Pharmaceuticals has a one year low of $4.41 and a one year high of $9.75. The stock has a market capitalization of $281.29 million, a P/E ratio of -12.98 and a beta of 1.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.14). Pieris Pharmaceuticals had a negative net margin of 65.40% and a negative return on equity of 96.56%. The business had revenue of $4.15 million during the quarter, compared to the consensus estimate of $11.39 million. research analysts anticipate that Pieris Pharmaceuticals will post -0.48 earnings per share for the current year.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Analyst Recommendations for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply